NASDAQ:RDHL RedHill Biopharma (RDHL) Stock Forecast, Price & News $2.05 +0.02 (+0.99%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$2.01▼$2.0850-Day Range$2.01▼$4.4452-Week Range$1.98▼$49.20Volume35,294 shsAverage Volume57,242 shsMarket Capitalization$8.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About RedHill Biopharma (NASDAQ:RDHL) StockRedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.Read More Receive RDHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address RDHL Stock News HeadlinesMay 24, 2023 | bizjournals.comRaleigh drug developer trims R&D pipeline, shifts resourcesMay 22, 2023 | finance.yahoo.comRedHill Provides R&D UpdateJune 8, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 15, 2023 | finance.yahoo.comRedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares DeficiencyMay 9, 2023 | finance.yahoo.comRedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease WeekMay 6, 2023 | americanbankingnews.comStockNews.com Upgrades RedHill Biopharma (NASDAQ:RDHL) to "Hold"May 1, 2023 | finance.yahoo.comRedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology SettingApril 28, 2023 | finanznachrichten.deRedHill Biopharma Ltd.: RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational HighlightsJune 8, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.April 28, 2023 | finance.yahoo.comRedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational HighlightsApril 17, 2023 | finance.yahoo.comBenign Growth For RedHill Biopharma Ltd. (NASDAQ:RDHL) Underpins Stock's 41% PlummetApril 11, 2023 | finance.yahoo.comRedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementApril 3, 2023 | finance.yahoo.comRedHill Biopharma Announces Closing of $6 Million Registered Direct OfferingMarch 30, 2023 | finance.yahoo.comRedHill Biopharma Announces $6 Million Registered Direct OfferingMarch 25, 2023 | americanbankingnews.comRedHill Biopharma (NASDAQ:RDHL) Receives New Coverage from Analysts at StockNews.comMarch 23, 2023 | finance.yahoo.comRedHill Biopharma Ltd.'s (NASDAQ:RDHL) market cap dropped US$146m last week; Individual investors bore the bruntMarch 23, 2023 | finanznachrichten.deRedHill Biopharma Ltd: RedHill Biopharma Announces Plan to Implement ADS Ratio ChangeMarch 21, 2023 | finance.yahoo.comRedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-RespondersMarch 16, 2023 | finance.yahoo.comRedHill Biopharma Announces Plan to Implement ADS Ratio ChangeMarch 8, 2023 | finance.yahoo.comRedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single InvestorFebruary 28, 2023 | finance.yahoo.comRedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures ProgramFebruary 28, 2023 | finance.yahoo.comRedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For DevelopmentFebruary 16, 2023 | baystreet.caRedHill Flat on Application for Oncology DrugFebruary 16, 2023 | finance.yahoo.comRedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology SupportFebruary 16, 2023 | finance.yahoo.comRedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA PlanFebruary 15, 2023 | finance.yahoo.comRedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation SyndromeFebruary 10, 2023 | finance.yahoo.comRaleigh pharma sheds debt in exchange for top-selling drug. Now what?See More Headlines RDHL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RDHL Company Calendar Last Earnings11/30/2021Today6/08/2023Next Earnings (Estimated)6/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RDHL CUSIPN/A CIK1553846 Webwww.redhillbio.com Phone972-3541-3131Fax972-3541-3144Employees201Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($62.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,670,000.00 Net Margins-115.97% Pretax Margin-115.97% Return on EquityN/A Return on Assets-44.03% Debt Debt-to-Equity RatioN/A Current Ratio0.44 Quick Ratio0.38 Sales & Book Value Annual Sales$61.80 million Price / Sales0.13 Cash FlowN/A Price / Cash FlowN/A Book Value($16.41) per share Price / Book-0.12Miscellaneous Outstanding Shares3,930,000Free Float3,667,000Market Cap$8.06 million OptionableOptionable Beta2.11 Key ExecutivesMr. Dror Ben-Asher (Age 56)Co-Founder, Chairman & CEO Comp: $884.67kMr. Micha Ben-Chorin (Age 53)Chief Financial Officer Comp: $548.14kMr. Gilead Raday MPhil (Age 47)MSc, Chief Operating Officer Comp: $539.74kMr. Adi Frish (Age 52)Chief Corp. & Bus. Devel. Officer Comp: $519.65kMr. Rick D. Scruggs (Age 62)Chief Commercial Officer, Pres of RedHill Biopharma Inc. & Director Comp: $736.35kDr. Mark L. Levitt M.D.Ph.D., Chief Scientific OfficerMs. Alexandra OkmianSr. Bus. Devel. & Investor Relations Mang.Kristin ComerVP, Gen. Counsel & Chief Compliance OfficerMs. Valerie GraceffaVP of SalesMr. Rob JacksonSr. VP of Sales & MarketingMore ExecutivesKey CompetitorsCalciMedicaNASDAQ:CALCGraybug VisionNASDAQ:GRAYZyVersa TherapeuticsNASDAQ:ZVSACohBarNASDAQ:CWBRExicureNASDAQ:XCURView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 260,000 shares on 5/16/2023Ownership: 9.612%Belvedere Trading LLCSold 9,500 shares on 5/15/2023Ownership: 0.000%Acadian Asset Management LLCSold 636,793 shares on 5/11/2023Ownership: 0.850%Simplex Trading LLCSold 4,500 shares on 4/27/2023Ownership: 0.000%View All Institutional Transactions RDHL Stock - Frequently Asked Questions How have RDHL shares performed in 2023? RedHill Biopharma's stock was trading at $5.6120 at the beginning of the year. Since then, RDHL stock has decreased by 63.5% and is now trading at $2.05. View the best growth stocks for 2023 here. Are investors shorting RedHill Biopharma? RedHill Biopharma saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 116,600 shares, a decrease of 31.7% from the April 30th total of 170,700 shares. Based on an average daily trading volume, of 97,100 shares, the short-interest ratio is presently 1.2 days. Approximately 4.0% of the company's shares are short sold. View RedHill Biopharma's Short Interest. When is RedHill Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 22nd 2023. View our RDHL earnings forecast. How were RedHill Biopharma's earnings last quarter? RedHill Biopharma Ltd. (NASDAQ:RDHL) announced its quarterly earnings data on Tuesday, November, 30th. The biotechnology company reported ($20.00) EPS for the quarter, missing the consensus estimate of ($19.20) by $0.80. The biotechnology company earned $21.61 million during the quarter, compared to analysts' expectations of $23.41 million. During the same period in the previous year, the company posted ($20.00) EPS. When did RedHill Biopharma's stock split? Shares of RedHill Biopharma reverse split on the morning of Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of RedHill Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA). What is RedHill Biopharma's stock symbol? RedHill Biopharma trades on the NASDAQ under the ticker symbol "RDHL." Who are RedHill Biopharma's major shareholders? RedHill Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (9.61%), Acadian Asset Management LLC (0.85%), Belvedere Trading LLC (0.00%) and Simplex Trading LLC (0.00%). How do I buy shares of RedHill Biopharma? Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is RedHill Biopharma's stock price today? One share of RDHL stock can currently be purchased for approximately $2.05. How much money does RedHill Biopharma make? RedHill Biopharma (NASDAQ:RDHL) has a market capitalization of $8.06 million and generates $61.80 million in revenue each year. The biotechnology company earns $-71,670,000.00 in net income (profit) each year or ($62.40) on an earnings per share basis. How many employees does RedHill Biopharma have? The company employs 201 workers across the globe. How can I contact RedHill Biopharma? RedHill Biopharma's mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The official website for the company is www.redhillbio.com. The biotechnology company can be reached via phone at 972-3541-3131, via email at investors@redhillbio.com, or via fax at 972-3541-3144. This page (NASDAQ:RDHL) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RedHill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.